GlassScriptPhysician profile
Carlos Luis Perez
NPI 1598783870
$8,997.21
in general payments reported to CMS, 2019-2025
37 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $741 · 2021: $1,370 · 2022: $1,877 · 2023: $1,516 · 2024: $1,327 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,026 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,025.57 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,275.05 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $867.36 | 2019-2024 | Yupelri |
| Genzyme Corporation | $767.82 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $712.23 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Mallinckrodt Hospital Products INC. | $491.35 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.87 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $369.33 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $346.42 | 2020-2025 | Trintellix, Glassia |
| Grifols USA, LLC | $338.08 | 2019-2024 | Prolastin-C Liquid |
| Insmed, INC. | $292.45 | 2021-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $279.67 | 2019-2024 | Uptravi, Opsumit |
| Abbvie INC. | $236.06 | 2021-2024 | |
| Philips North America LLC | $181.38 | 2021-2025 | Vest Therapy Und |
| United Therapeutics Corporation | $174.14 | 2022-2024 | Tyvaso |
| Pfizer INC. | $169.64 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $149.22 | 2019 | |
| Electromed, INC. | $115.17 | 2022-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $81.34 | 2019-2021 | |
| Pulmonx Corporation | $77.81 | 2021 | |
| Inspire Medical Systems, INC. | $76.66 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $67.27 | 2024 | Givlaari |
| Teva Pharmaceuticals USA, INC. | $66.24 | 2021 | |
| Intuitive Surgical, INC. | $57.90 | 2022 | |
| Viatris Specialty LLC | $34.40 | 2025 | Yupelri |
| Novo Nordisk INC | $34.16 | 2025 | Ozempic, Rybelsus, Wegovy |
| Eisai INC. | $33.63 | 2021 | |
| Amgen INC. | $32.80 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $30.49 | 2019 | |
| Lilly USA, LLC | $24.68 | 2024 | Zepbound, Jardiance |
| Allergan, INC. | $18.23 | 2019 | |
| Gilead Sciences, INC. | $17.66 | 2021 | |
| Inogen, INC. | $16.94 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.64 | 2021 | |
| Ani Pharmaceuticals, INC. | $16.25 | 2023 | Purified Cortrophin Gel |
| Genentech USA, INC. | $14.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.